Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) EBIT (2022 - 2025)

Zentalis Pharmaceuticals has reported EBIT over the past 4 years, most recently at -$37.4 million for Q4 2025.

  • Quarterly results put EBIT at -$37.4 million for Q4 2025, up 24.99% from a year ago — trailing twelve months through Dec 2025 was -$152.8 million (up 20.08% YoY), and the annual figure for FY2025 was -$152.8 million, up 20.08%.
  • EBIT for Q4 2025 was -$37.4 million at Zentalis Pharmaceuticals, down from -$33.7 million in the prior quarter.
  • Over the last five years, EBIT for ZNTL hit a ceiling of -$24.8 million in Q1 2024 and a floor of -$103.9 million in Q2 2023.
  • Median EBIT over the past 4 years was -$53.0 million (2022), compared with a mean of -$54.4 million.
  • Biggest five-year swings in EBIT: soared 61.87% in 2024 and later plummeted 84.22% in 2025.
  • Zentalis Pharmaceuticals' EBIT stood at -$51.8 million in 2022, then crashed by 31.24% to -$67.9 million in 2023, then grew by 26.61% to -$49.8 million in 2024, then grew by 24.99% to -$37.4 million in 2025.
  • The last three reported values for EBIT were -$37.4 million (Q4 2025), -$33.7 million (Q3 2025), and -$36.1 million (Q2 2025) per Business Quant data.